Daiichi Sankyo, a global pharmaceutical company, is seeking novel oligonucleotide-based approaches to efficiently and specifically increase or decrease target RNAs both in vitro and in vivo for developing new treatments. Additionally, cutting-edge RNA editing techniques are also of interest.
Approaches of Interest:
<ul>
<li>Novel oligonucleotide-based technology that can control RNA expression levels or change RNA sequences e.g., dual-targeting antisense oligonucleotides (ASOs) and advanced RNA editing technologies</li>
<li>Novel technologies for efficient transport from extracellular space into cytosol, nucleus or mitochondria e.g., chemically modified oligonucleotides to enhance transport from the cytosol into the nucleus</li>
<li>Novel target-identification methods for oligonucleotide-based approaches such as ASO and RNA editing</li>
<li>Research findings on novel biological regulatory pathways or molecules that control RNA transcription, splicing, translation, or transport, with potential for future development as described in the previous three bullet points
<ul>
<li>Opportunities should demonstrate how the newly identified RNA targets could contribute to treating specific diseases</li>
</ul>
</li>
</ul>
Out of Scope:
<ul>
<li>Packaging technologies/delivery systems (e.g. viral vectors, nanoparticles)</li>
<li>For submissions relating to ASOs, RNA editing techniques, and conventional technologies that modulate RNA by endogenous Ago2, RNase H or ADAR are out of scope</li>
<li>Submissions based on hypothetical ideas or lacking sufficient proof-of-concept</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Submissions must include, at minimum, in vitro data; in vivo data is preferred </li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this <a href="">submission form</a>. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Daiichi Sankyo is seeking novel oligonucleotide-based approaches to increase or decrease target RNAs both in vitro and in vivo for developing new treatments. Cutting-edge RNA editing techniques are also of interest.

Innovative Oligonucleotide Strategies for Targeted RNA Expression Modulation

Daiichi Sankyo, a global pharmaceutical company, is seeking evaluation systems and biomarkers suitable for non-clinical studies in the fields of neurodegenerative diseases (ALS, AD) with high translational potential for clinical application. In the immunology domain, their interest is specifically limited to systems for accurately predicting human immunogenicity caused by intracellularly expressed proteins from gene therapy. 
Approaches of Interest:
<ul>
<li>Evaluation systems and biomarkers in neurodegenerative diseases
<ul>
<li>In vitro and in vivo evaluation models with human translatability that replicate multiple aspects, such as loss of function and gain of toxic function, of TDP-43 proteinopathy in ALS alone</li>
<li>Potential biomarkers for ALS that reflect either gain-of-function (GoF) or loss-of-function (LoF) mechanisms of TDP-43, or both, identified through analyses of patient-derived samples (e.g., STMN2, UNC13A mis-splicing)</li>
<li>Potential biomarkers for AD that predict disease progression rate after onset, identified through analyses of patient-derived samples</li>
</ul>
</li>
<li>Systems for accurately predicting human immunogenicity caused by intracellularly expressed proteins from gene therapy
<ul>
<li>Excluding secreted proteins circulating in blood</li>
<li>In silico models are out of scope</li>
</ul>
</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>All stages of research are of interest for evaluations systems and biomarkers providing there is proof-of-concept</li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this <a href="">submission form</a>. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include project/PhD funding and research collaborations.

Daiichi Sankyo is seeking evaluation systems and biomarkers suitable for non-clinical studies in the fields of neurodegenerative diseases. In the immunology domain, they are interested in systems for accurately predicting human immunogenicity .

Development and Identification of Novel Evaluation Systems and Biomarkers for Gene Therapy in Neurodegenerative Diseases and Immunology

BSM Biotech Holding seeks innovative discovery research projects in the oncology field, to identify novel therapeutic approaches for further development. BSM expects to form new companies in collaboration with the research teams based on their technology, either by licensing deals or transfer of the technologies to the company. 
Approaches of Interest:
<ul>
<li>BSM Biotech Holding’s focus is the oncology space, in particular immuno-oncology, cancer stem cell therapy, epigenetic regulators and precision medicine based on genetic and/or molecular biomarkers. </li>
<li>Solid cancers are of high interest; however haematological cancers are also within scope.</li>
<li>All mechanisms of actions are of interest, and any modalities including mAb’s, small molecules, ADC’s, aptamers, bi/trispecific molecules and modalities regulating gene expression.</li>
</ul>
Out of Scope:
<ul>
<li>Cell therapy approaches. </li>
<li>Diagnostics (unless companion diagnostics), medical devices, nutrition, OTC products. </li>
<li>Repurposing and reformulation of therapeutics.</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Target validation and hit identification are minimum requirements. </li>
<li>Preferably in vitro validation data should be obtained, evidencing that the drug functions at the molecular/cellular level.</li>
<li>In vivo data indicative of efficacy and safety also desirable.</li>
<li>Approaches should have at least hit molecules identified and IP filed or under preparation to be filed allowing for asset protection in USA, Europe, and Japan, as a minimum.</li>
</ul>
Submission Information
Submission of 200–300-word briefs and presentations summarizing the opportunity are encouraged, along with any optional supplementary information e.g. relevant publications, patent information etc. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
Opportunity for Collaboration
BSM’s experienced management team looks to in-license discovery research projects in oncology, to fund them and spin them off into separate project-focussed companies. BSM will closely collaborate with the innovators to capitalize on their know-how and technologies. Funding and support are available on a case-by-case basis, depending on the technology and development needs.

BSM Biotech Holding seeks to develop discovery research projects in the immuno-oncology field into spin-off companies.

Seeking Novel Therapeutic Approaches in Oncology

ICL Group, a leading producer of phosphoric acid for chemical manufacturing, is seeking novel and mature solutions to remove or treat organic impurities from the phosphoric acid production process. Approaches that target all stages of the manufacturing process are in scope, including mining and beneficiation of phosphate rock, acid production, and post-processing, with the earlier stages being highest priority. Solutions should reduce the organic content in merchant grade phosphoric acid to industry-acceptable levels. 
Approaches of Interest:
<ul>
<li>The impurities of highest interest are organic impurities, mainly humic acid and fulvic acid</li>
<li>Solutions need to be able to work in harsh conditions and be able to withstand dust, fluorine, high temperatures, and high acidity</li>
<li>Solutions that are cost effective, scalable for large industrial plants, and are environmentally sustainable are of highest priority </li>
<li>Processes that use catalysts are in scope </li>
</ul>
Out of Scope:
<ul>
<li>Approaches that aren’t cost effective at industrial scale </li>
<li>Approaches that can’t withstand the harsh operational conditions (e.g. UV-based) </li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Opportunities must have at least pilot-scale proof of concept (TRL 5), better to have even higher as the idea is to implement the solution quickly and initiate the industrial project by Q4, 2026 </li>
<li>Priority will be given to later stage solutions with demonstrated efficacy in operational environments </li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions should provide a clear description of the technology and proof-of-concept data. Submissions that also include cost estimates will be prioritized. This campaign is open to submissions from SMEs and start-up companies. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, service agreements, or ongoing collaborations.

ICL Group is seeking novel solutions to remove organic impurities, such as humic acid and fulvic acid, from any stage of phosphoric acid production.

Reducing Organic Impurities in Phosphoric Acid Production

Daiichi Sankyo, a global pharmaceutical company, is seeking a fully cell‑free, in vitro technology capable of synthesizing and amplifying plasmid DNA without relying on E. coli. 
Approaches of Interest:
<ul>
<li>Recombination Assembly Methods
<ul>
<li>Methods that can reproduce a highly efficient homologous recombination system of microorganisms in vitro, resulting in seamless DNA ligation </li>
<li>Methods that can correctly assemble and integrate 50 or more DNA fragments at once via a timely (less than 30 minute) isothermal reaction</li>
</ul>
</li>
<li>Replication Cycle Reaction Methods
<ul>
<li>Able to mimic the E. coli genome replication system in vitro using a reconstituted set of proteins for amplification</li>
<li>Amplification of a single circular DNA molecule in a time-effective manner</li>
<li>Enables amplification of long circular DNA molecules exceeding 10 kb in vitro</li>
<li>Can achieve high application accuracy, exceeding that of traditional PCR</li>
</ul>
</li>
</ul>
Out of Scope:
<ul>
<li>Replication systems in E. coli</li>
<li>Technologies costing over ten times more than conventional E. coli culture methods</li>
<li>Technologies requiring dedicated equipment with initial investments exceeding 100 million yen</li>
<li>Methods taking over one week per plasmid to generate</li>
<li>Opportunities relating to minicircle DNA or mRNA</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Daiichi Sankyo is seeking basic research accompanied by experimental verification</li>
<li>Methods must be established</li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Daiichi Sankyo is seeking a fully cell‑free, in vitro technology capable of synthesizing and amplifying plasmid DNA without relying on E. coli. 

Cell-free Synthesis of Transfection-grade Plasmid DNA for Automated Processing

Daiichi Sankyo, a global pharmaceutical company, is seeking disease models of macular degeneration-specifically atrophic age-related macular degeneration (AMD) and Stargardt disease-that have high translational potential for clinical use. To this end, they are seeking disease models that are induced by fundamental pathological mechanisms known in AMD or that have demonstrated responsiveness to existing AMD therapies
Approaches of Interest:
<ul>
<li>In vitro and in vivo disease models that are close to human disease states in terms of disease state inducers, gene expression, and pathology</li>
<li>The model should meet at least two of the following criteria:
<ul>
<li>It is induced by factors that are strongly associated with AMD</li>
<li>It demonstrates concordance with human pathology, such as the development of CNV or localized RPE atrophy</li>
<li>It shows responsiveness to agents that have exhibited efficacy signals in AMD clinical trials, including complement inhibitors</li>
</ul>
</li>
<li>Research to evaluate the efficacy of drugs using above AMD and Stargardt disease models </li>
</ul>
Out of Scope:
<ul>
<li>Models that are not applicable to age-related macular degeneration or Stargardt disease</li>
<li>In silico and AI powered models</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Opportunities from basic research to preclinical research are within scope</li>
<li>Opportunities with animal models or in vitro RPE cell models are of highest interest</li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Daiichi Sankyo is seeking disease models of macular degeneration that are induced by fundamental pathological mechanisms known in AMD or that have demonstrated responsiveness to existing AMD therapies.

Seeking Novel Disease Models of Macular Degeneration

Nissan Chemical Corporation, a forerunner in chemical innovations, is seeking novel ASO and siRNA therapeutics for CNS and liver diseases. They are especially interested in therapeutics that are facing challenges with toxicity, stability, and efficacy, which may be able to leverage their proprietary platform which incorporates 2’-O-[2-(N-methylcarbamoyl)ethyl] (MCE)-modified nucleotides to overcome these challenges. 
Approaches of Interest: 
<ul>
<li>Diseases of interest include rare and neurodegenerative CNS diseases (e.g. ALS, inherited ataxias), rare metabolic and liver fibrosis diseases (e.g. MASH, PBC, PSC), and conditions caused by hepatocyte-secreted proteins (e.g. complement-related disorders, hemophilia) </li>
<li>Therapeutics for CNS disorders could be delivered locally (e.g. via intrethecal or intracerebroventricular injection) or systemically with BBB-penetrating technologies. For liver disorders, therapeutics should be administered systemically and act within hepatocytes. </li>
<li>Therapeutics that work through gene silencing are highest priority </li>
<li>Novel gene and protein targets for diseases of interest are in scope </li>
</ul>
Out of Scope: 
<ul>
<li>Ultra-rare CNS and liver diseases (i.e. less than 1000 patients globally) </li>
<li>Therapeutics that act via gene upregulation </li>
<li>Other nucleic acid therapeutics (e.g. aptamers, miRNA) </li>
<li>Novel chemically modified nucleic acid platforms </li>
</ul>
Developmental Stages of Interest: 
<ul>
<li>Opportunities from basic research to late preclinical are in scope, provided there is in vivo proof of concept </li>
</ul>
Submission Information and Opportunity for Collaboration 
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
Nissan Chemical Corporation is looking to establish research collaborations with partners who would be able to leverage their MCE-ASO/siRNA platform, which incorporates MCE-modified nucleotides. This unique chemistry is engineered to provide enhanced nuclease resistance, minimize hepatotoxicity and neurotoxicity, and improve knockdown efficacy and durability in vivo. They may also consider strategic investment.

Nissan Chemical Corporation is seeking novel antisense oligonucleotide and siRNA therapeutics in development for CNS and liver disorders that are facing challenges with toxicity, stability, and efficacy.

ASO and siRNA Therapeutics for CNS and Liver Disorders 

AstraZeneca is seeking datasets or physical/virtual libraries of macrocyclic peptides that can help map and model the property space required for oral and cell permeable macrocyclic peptides. They particularly welcome: 
<ul>
<li>Annotated in vitro/vivo datasets describing permeability, oral bioavailability, enzymatic stability or other relevant properties of peptide macrocycles—including both proprietary and published collections</li>
<li>Libraries of macrocyclic peptides which are suitable for screening, ideally with reference activity which would enable AI-led property mapping and predictive modelling. Physical compound sets are preferred but virtual libraries may be accepted for use once training datasets have been established</li>
<li>Novel or proprietary methods for predicting, quantifying, or modelling the physicochemical space that governs permeability and oral absorption in macrocyclic peptides</li>
</ul>
Out of scope: Proposals that are hypothetical, lack experimental feasibility, or involve low-throughput experimental or predictive modelling approaches that are not scalable for parallel evaluation of large compound sets will be given a lower priority.
Submission and Programme Information and Opportunity for Collaboration
AstraZeneca invites applications from both academic and biotech organizations. Applicants should complete the <a href="">proposal form</a> which should contain a brief, non‑confidential overview of your proposal, including a workplan, approximate budgetary requirements, desired outcomes, and background on your research group. To submit your proposal, please visit the <a href="">Inpart website</a>, register, and submit your application form under the appropriate campaign. Submissions should either provide experimental proof-of-concept, published evidence, or actionable approaches for generating datasets or screening tools that address these key parameters. Solutions that enable parallel evaluation of multiple macrocyclic peptides, or which deliver mechanistic or predictive insights into the determinants of oral and cell permeability, are particularly encouraged. Further details on the solution criteria can be found in the proposal form.
AstraZeneca’s CoSolve challenge is a global Open Innovation programme seeking collaborators with innovative solutions to real research challenges. These challenges lie within the company’s R&amp;D research focus areas and require solutions that are immediately translatable. Collaborators are sought who can bring innovative ideas that can be rapidly translated into tangible solutions. Working together, these ideas could help shape the development and delivery of new therapies and bring them to patients sooner. Applications that are of interest will be selected to participate in the virtual Challenge Week - an intensive week where applicants will pitch their ideas and work with AstraZeneca scientists to transform their idea into a workplan. For selected winners from the challenge week, a <a href="">collaboration agreement</a> will be put in place with specified milestones and the winning projects can begin quickly. Details about the collaboration benefits can be found in the proposal form.

AstraZeneca is seeking datasets or physical/virtual libraries of macrocyclic peptides that can help map and model the property space required for oral and cell permeable macrocyclic peptides. 

AI/ML-ready Datasets for Peptide Permeability & Oral Bioavailability or Macrocyclic Peptide Screening Libraries to Enable Oral, Cell-permeable Macrocycle Design

AstraZeneca aims to build a world class peptide discovery platform, combining phage and mRNA display technologies and amenable to the incorporation of a wide variety of non-canonical amino acids (ncAAs) in those display systems, from ncAAs capable of forming covalent bonds to enable new chemistries in peptides, such as cyclization, to ncAAs which can introduce novel physicochemical properties, such as altered hydrophobicity, charge, or backbone rigidity, to manipulate peptide solubility, cellular uptake, or overall structural dynamics.
The team at AstraZeneca is seeking solutions for the efficient incorporation of ncAAs in phage and/or mRNA display systems that allow for thioether macrocycle cyclisation and/or efficient incorporation of a range of amino acids. Proposed solutions to this challenge should meet the following solution requirements to be considered for funding by AstraZeneca. The selected collaborator will need to provide AstraZeneca with reagents allowing for at least one of the following: 
<ul>
<li>Efficient incorporation of ncAAs allowing for thioether macrocycle cyclisation in a phage display system. This should go beyond the simple use of evolved tRNA synthetases and overcome some of the limitations of stop codon reprogramming</li>
<li>Efficient incorporation of ncAAs allowing for thioether macrocycle cyclisation in an mRNA display/cell free protein expression system</li>
<li>Incorporation of other types of ncAA such as but not limited to N-methylated amino acids, fluorosulphate-amino acid, Aib, in an mRNA display/cell free protein expression system</li>
</ul>
Submission and Programme Information and Opportunity for Collaboration
AstraZeneca invites applications from both academic and biotech organizations. Applicants should complete the <a href="">proposal form</a> which should contain a brief, non‑confidential overview of your proposal, including a workplan, approximate budgetary requirements, desired outcomes, and background on your research group. To submit your proposal, please visit the <a href="">Inpart website</a>, register, and submit your application form under the appropriate campaign. Further details on the solution criteria can be found in the proposal form.
AstraZeneca’s CoSolve challenge is a global Open Innovation programme seeking collaborators with innovative solutions to real research challenges. These challenges lie within the company’s R&amp;D research focus areas and require solutions that are immediately translatable. Collaborators are sought who can bring innovative ideas that can be rapidly translated into tangible solutions. Working together, these ideas could help shape the development and delivery of new therapies and bring them to patients sooner. 
Applications that are of interest will be selected to participate in the virtual Challenge Week - an intensive week where applicants will pitch their ideas and work with AstraZeneca scientists to transform their idea into a workplan. For selected winners from the challenge week, a <a href="">collaboration agreement</a> will be put in place with specified milestones and the winning projects can begin quickly.

AstraZeneca is seeking solutions for the efficient incorporation of ncAAs in phage and/or mRNA display systems that allow for thioether macrocycle cyclisation and/or efficient incorporation of a range of amino acids.

Non-canonical Amino Acids for in vitro Display Systems

AstraZeneca is seeking screening assays, or predictive models relevant to oral bioavailability and/or cell permeability of macrocyclic peptides that can help map and model the property space required for oral and cell-permeable macrocyclic peptides. They particularly welcome: 
<ul>
<li>High-throughput screening assays (in vitro and ex vivo) or advanced in silico platforms for quantifying key properties relevant to oral bioavailability and/or cellular permeability of macrocyclic peptides</li>
<li>Novel or proprietary methods for predicting, quantifying, or modelling the physicochemical space that governs permeability and oral absorption in macrocyclic peptides</li>
<li>Annotated data generated from these screening methods</li>
</ul>
The selected collaborator will receive at least 8 benchmark compounds to confirm permeability ranking in a blinded study. Following screening, compounds will be unblinded for the collaborator and available to use freely. 
Out of scope: Proposals that are hypothetical, lack experimental feasibility, or involve low-throughput experimental or predictive modelling approaches that are not scalable for parallel evaluation of large compound sets will be given a lower priority. 
Submission and Programme Information and Opportunity for Collaboration
AstraZeneca invites applications from both academic and biotech organizations. Applicants should complete the <a href="">proposal form</a> which should contain a brief, non‑confidential overview of your proposal, including a workplan, approximate budgetary requirements, desired outcomes, and background on your research group. To submit your proposal, please visit the <a href="">Inpart website</a>, register, and submit your application form under the appropriate campaign. Proposed collaborations or data contributions should either provide experimental proof-of-concept, published evidence, or actionable approaches for generating datasets or screening tools that address these key parameters. Solutions that enable parallel evaluation of multiple macrocyclic peptides, or which deliver mechanistic or predictive insights into the determinants of oral and cell permeability, are particularly encouraged. Further details on the solution criteria can be found in the proposal form.
AstraZeneca’s CoSolve challenge is a global Open Innovation programme seeking collaborators with innovative solutions to real research challenges. These challenges lie within the company’s R&amp;D research focus areas and require solutions that are immediately translatable. Collaborators are sought who can bring innovative ideas that can be rapidly translated into tangible solutions. Working together, these ideas could help shape the development and delivery of new therapies and bring them to patients sooner. Applications that are of interest will be selected to participate in the virtual Challenge Week - an intensive week where applicants will pitch their ideas and work with AstraZeneca scientists to transform their idea into a workplan. For selected winners from the challenge week, a <a href="">collaboration agreement</a> will be put in place with specified milestones and the winning projects can begin quickly. Details about the collaboration benefits can be found in the proposal form.

AstraZeneca is seeking established screening assays relevant to oral bioavailability and/or cell permeability of macrocyclic peptides that can help map and model the property space required for oral and cell-permeable macrocyclic peptides. 

High Throughput Screening Assays to Map Macrocyclic Peptide Permeability and Stability Properties

Certis Belchim, an expert in crop protection, is seeking novel technologies to optimize the production and reduce the application cost of its herbicide, metobromuron. Specifically, the team is interested in approaches that reduce the cost to produce the metobromuron compound or formulation improvements that reduce the dose rate of the herbicide. All approaches should be able to be scaled up to industrial quantities. In the evaluation of the proposals a feasibility study will be made. Ballpark prices of final proposal or cost reduction benchmarks with the proposed technologies are highly appreciated.
Optimization of the production process:
<ul>
<li>New chemical synthesis methods that achieve minimum gram level quantities, preferentially kg or ton level </li>
<li>Open for new production technologies, e.g. continuous flow reactors, enzymatic production, etc. </li>
<li>Improvements that make the production process more environmentally friendly are also of interest </li>
</ul>
Optimization of the formulation:
<ul>
<li>Open to a range of formulation methods, e.g. capsule suspensions, oil-based formulations, etc. </li>
<li>Adjuvants and enhancers that reduce the dose rate of the herbicide are of interest </li>
<li>Mixtures of metobromuron with other herbicides that would achieve the same effect with a reduced cost </li>
</ul>
Out of Scope:
<ul>
<li>Chemical syntheses that only achieve microgram quantities </li>
<li>Novel herbicides and methods that cannot be applied to metobromuron </li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Opportunities should have at least lab-based proof of concept with a relevant example compound </li>
</ul>
Submission Information and Opportunity for Collaboration
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications and benchmarks on cost improvements are highly appreciated. This campaign is open to submissions from SMEs and start-up companies. Submitters ideally have experience on industrial scale. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations. Successful submissions could lead to a joint development program with Certis Belchim to develop the approach on an industrial scale.

Certis Belchim is seeking approaches to optimize the production process and formulation of the herbicide metobromuron.

Seeking Approaches to Reduce the Application Cost of an Agrochemical Active Ingredient

Daiichi Sankyo, a global pharmaceutical company, is seeking research on in vivo animal models and in vitro cell/tumor tissue models exhibiting resistance to immune checkpoint inhibitors (ICIs).
<h3>Approaches of Interest:</h3>
<ul>
<li>The mechanism of resistance (MoR) is clearly defined and is tumor-intrinsic </li>
<li>The PD-1 and PD-L1 immune checkpoint pathways are of highest interest</li>
<li>Research focused on solid tumors (lung, breast and pancreatic tumors are of primary interest)</li>
<li>The MoR to ICI reflects clinical observations </li>
<li>The MoR to ICI is associated with specific patient selection biomarker </li>
</ul>
<h3>Out of Scope:</h3>
<ul>
<li>Submissions relating to blood cancers </li>
<li>Opportunities that lack a clear MoR or have tumor-extrinsic MoR </li>
</ul>
<h3>Developmental Stages of Interest:</h3>
<ul>
<li>Opportunities from basic research to registration are in scope providing there is a clear MoR</li>
</ul>
<h3>Submission Information</h3>
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this <a href="">submission form</a>. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
<h3>Opportunity for Collaboration</h3>
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Daiichi Sankyo is seeking research on in vivo animal models and in vitro cell/tumor tissue models exhibiting resistance to immune checkpoint inhibitors. 

Seeking In Vivo and In Vitro Models Exhibiting Resistance to Immune Checkpoint Inhibitors

The Impulse by Chiesi, the Open Innovation team within the global research-oriented biopharmaceutical group, is launching a call for opportunities focused on novel drug delivery systems to enhance drug targeting and patient outcomes. Through Inpart Connect, the team seeks innovative solutions in three defined areas of interest.
Oral delivery of biologics - oral administration of peptides, proteins or more complex biotherapeutics to support home-based care, improve adherence and simplify treatment. Approaches should address enzymatic degradation and poor intestinal absorption, which restrict the feasibility of oral delivery. Novel formulations, devices, or enabling technologies are within scope. 
Non-Invasive delivery to bypass the blood-brain-barrier - enhance therapeutic outcomes and patient experience, by enabling non-invasive drug delivery routes (e.g. intranasal) that bypass the blood-brain barrier. Solutions that improve targeting efficiency, bioavailability, and ease of use, whether through novel formulations, devices, or biological mechanisms.
Personalized and customizable delivery systems for ultra-precise dosing - delivery systems to tailor dosing for individual needs, which is critical in areas like paediatrics, geriatrics and rare diseases. Any solution that allows flexible, on-demand production of personalized dosage forms, with priority given to modular, scalable platforms. Strategies to enable doses to be adapted based on patient-specific characteristics such as age, weight, disease progression, or monitored clinical indicators (e.g., biomarkers, organ function), enabling dynamic and responsive treatment strategies. 
<ul>
<li>Oral, lung, nasal, parenteral intranasal, and other non-invasive approaches are in scope.</li>
<li>Developmental Stages of Interest: Solutions with TRL 3-6 are of high interest. Submissions should have a minimum of in vitro validation, with a preference for in vivo data or first in-human studies. </li>
<li>Out of Scope: Diagnostic approaches or methods, analytical technologies, oral delivery of small molecules. Submissions from individual physicians or others working in hospital/private practice. </li>
</ul>
Submission Information: Submissions should include a one-page summary (200–300-words) along with any supplementary information such as relevant publications or patents. Applicants are strongly encouraged to include a slide-deck (or similar presentation) outlining their solution and plans to bring it to market for patient benefit. Chiesi welcomes submissions from all applicants, including early-stage researchers, using this <a href="">submission form</a> to describe their research and proposed next steps.
The Impulse by Chiesi is open to a range of collaboration models, including support for small proof-of-concept or pilot studies to validate solutions that align with its needs. Details regarding intellectual property and licensing will be discussed on a case‑by‑case basis. By submitting to this campaign, you confirm that your submission contains only non-confidential information.

Chiesi is seeking novel drug delivery solutions to achieve oral delivery of biologics, and non-invasive delivery of drugs across the blood-brain barrier.

Seeking Non-invasive and/or Personalized Delivery Systems for Complex Therapies

Daiichi Sankyo, a global pharmaceutical company, is seeking in vitro models to assess immune-mediated organ toxicity for drug safety, as well as advanced in vitro models to evaluate drug efficacy in breast and lung cancers.
Approaches of Interest:
<ul>
<li>Assessment of immune-mediated organ toxicity for drug safety
<ul>
<li>In vitro models to evaluate immune-mediated organ toxicities caused by pharmaceutical compounds, such as immuno-oncology drugs, in humans</li>
<li>The ability to detect the risk potential of drug-induced immune-mediated organ toxicity in humans using appropriate endpoint evaluations and to justify the validity of those evaluations using clinical drugs</li>
<li>Evaluation models incorporating technologies such as Microphysiological Systems (MPS) or co-culture systems with immune cells are of interest, although a simpler and precise approach would be preferred </li>
<li>Models for all organs are of interest, with particular emphasis on vital systems including lung or heart </li>
</ul>
</li>
<li>In vitro assay models for drug efficacy assessment
<ul>
<li>Repeatable and quantitatively measurable in vitro assay models/systems using iPSC-derived cells and patient-derived organoids to assess drug efficacy for breast and lung cancers</li>
<li>Model should be validated using multiple existing drugs, and drug-resistant models are also of interest</li>
<li>Assay models incorporating technologies such as MPS and imaging analysis techniques are also of interest</li>
</ul>
</li>
</ul>
Out of Scope:
<ul>
<li>Single-use test systems for drug efficacy assessments</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Basic research through to clinical development with promising and unique technologies is within scope</li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this <a href="">submission form</a>. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, MTA, and research collaborations.

Daiichi Sankyo is seeking in vitro models to assess immune-mediated organ toxicity for drug safety, as well as advanced in vitro models to evaluate drug efficacy in breast and lung cancers.

In Vitro Assay Models for Drug Safety and Efficacy Assessment

A mid-cap publicly traded US Pharma company specializing in rare diseases with a highly efficient global commercial team is seeking assets for a wide range of rare disease indications that have reached clinical development. Our client’s pipeline consists of 3 products approved in several indications and 2 products in Phase 1-3. They are interested in expanding their portfolio with clinical-stage and commercial assets. 
<h3>Approaches of Interest: </h3>
<ul>
<li>Open to a wide range of therapeutic areas. A non-exhaustive list with some examples of diseases of interest can be found <a href="">here</a></li>
<li>Indications should have a patient population of 300 – 200,000 in the US</li>
<li>Open to a wide range of modalities, including small molecules, recombinant proteins, antibodies, and antisense oligonucleotides. Non-gene-therapy nucleic acid-based therapeutics are of particular interest </li>
<li>Repurposed drugs will be considered only if they have been reformulated into a new product for the rare indication </li>
</ul>
<h3>Out of Scope: </h3>
<ul>
<li>Cell therapy, gene therapy, and medical devices </li>
<li>Assets for oncology indications and psychiatric disorders </li>
<li>Assets that are under clinical development or marketed for non-rare indications </li>
<li>Generics, biosimilars, and natural products that are not IP-protected </li>
<li>Diagnostics and drug discovery platforms </li>
</ul>
<h3>Developmental Stages of Interest: </h3>
<ul>
<li>Opportunities from Phase 1 onwards (including commercial) are in scope </li>
<li>Opportunities that are Phase 2 onward are of highest interest </li>
</ul>
<h3>Submission Information </h3>
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. slide decks, relevant publications. Submissions that contain information on the therapeutic area, mechanism of action, modality, route of administration, patient population, and development stage will be prioritized. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
<h3>Opportunity for Collaboration </h3>
Our client is open to a range of collaboration opportunities, with the main focus on licensing of assets.

A mid-cap publicly traded US Pharma company specializing in rare diseases with a highly efficient global commercial team is seeking assets for a wide range of rare disease indications that have reached clinical development.

Engage with world leading R&D teams

Active campaigns

ico